1-14 of 14
Elisabeth Lange, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials

Othman Al-Sawaf, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Anna-Maria Fink, MD, Paula Cramer, Carmen D. Herling, MD PhD, Julia Von Tresckow, MD, Elisabeth Lange, MD, Sebastian Böttcher, MD PhD, Michael G. Kiehl, MD PhD, Martin Dreyling, MD, Ulrich Jaeger, Michael Gregor, MD, Ursula Vehling-Kaiser, MD, Matthias Ritgen, MD, Jan Dürig, MD, Eugen Tausch, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Valentin Goede, MD, Michael Hallek, MD, Barbara Eichhorst, MD, Petra Langerbeins, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139242
Published: 2020
Journal Articles

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Mathias J Rummel, MD PhD, Christian Lerchenmüller, MD, Manfred Hensel, MD, Martin Goerner, MD, Christian Buske, MD PhD, Holger Schulz, Burkhard Schmidt, MD, Georgi Kojouharoff, MD, Elisabeth Lange, MD, Wolfgang Willenbacher, MD PhD, Jan Dürig, Erik Engel, Frank Kauff, Jürgen Barth, Alexander Christoph Burchardt, MD, Axel Hinke, PhD, Jasmin Wupperfeld, Richard Greil, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 343.
https://doi.org/10.1182/blood-2019-121909
Published: 2019
Journal Articles

Prognostic Impact of Immunohistochemistry and MRD Results in Bone Marrow after Frontline Chemoimmunotherapy of Chronic Lymphocytic Leukemia (CLL): Results of Central Laboratory Analyses of the CLL10 Trial of the German CLL Study Group (GCLLSG)

Nadine Kutsch, MD, Sebastian Böttcher, MD PhD, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Christian Maurer, MD, Elisabeth Lange, MD, Hubert Köppler, MD, Michael G Kiehl, MD, Martin Sökler, MD, Rudolf Schlag, MD, Ursula Vehling-Kaiser, MD, Georg Köchling, MD, Christoph Plöger, MD, Michael Gregor, MD, Torben Plesner, MD, Ilske Oschlies, MD, Marco Herling, MD PhD, Kirsten Fischer, MD, Hartmut Döhner, MD, Michael Kneba, MD, Clemens-Martin Wendtner, MD, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD PhD, Anna Maria Fink, MD, Michael Hallek, MD, Wolfram Klapper, MD, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3021.
https://doi.org/10.1182/blood.V130.Suppl_1.3021.3021
Published: 2017
Journal Articles

Clinical Relevance of Alternatively Spliced Isoform AML1-ETO9a in Adult Patients with t(8;21)(q22;q22.1) Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG)

Mridul Agrawal, MDMSc, Andrea Corbacioglu, PhD, Daniela Weber, MSc, Verena I. Gaidzik, MD, Marianne Habdank, Nikolaus Jahn, MD, Thomas Michael Schroeder, MD, Thomas Kindler, MD, Mohammed Amen Wattad, MD, Michael Lübbert, Walter Fiedler, MD, Katharina S. Götze, MD, Mark Ringhoffer, MD, Jan Schleicher, MD, Elisabeth Lange, MD, Michael Pfreundschuh, MD, Martin Griesshammer, Richard Greil, MD, Heinz Kirchen, MD, Elisabeth Koller, MD, Felicitas Thol, MD, Jurgen Krauter, MD, Richard F. Schlenk, MD, Michael Heuser, MD, Arnold Ganser, MD, Lars Bullinger, MD, Peter Paschka, MD, Hartmut Döhner, MD, Konstanze Döhner, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2685.
https://doi.org/10.1182/blood.V130.Suppl_1.2685.2685
Published: 2017
Journal Articles

Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

Mathias J Rummel, Christian Buske, MD, Bernd Hertenstein, MD, Christian Lerchenmüller, MD, Michael Koenigsmann, MD, Elisabeth Lange, MD, Manfred Reeb, MD, Ulrich Kaiser, MD, Christina Balser, MD, Dirk Behringer, MD, Jan Dürig, MD, Tobias Gaska, MD, Georg Maschmeyer, MD, Georg Schliesser, MD, Alexander Christoph Burchardt, MD, Juergen Barth, Frank Kauff, Axel Hinke, PhD, Richard Greil, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 483.
https://doi.org/10.1182/blood.V130.Suppl_1.483.483
Published: 2017
Journal Articles

Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG)

Mridul Agrawal, MD, Andrea Corbacioglu, PhD, Peter Paschka, MD, Daniela Weber, Verena I. Gaidzik, MD, Nikolaus Jahn, MD, Andrea Kündgen, MD, Thomas Kindler, MD, Mohammad Amen Wattad, MD, Michael Lübbert, MD, Walter Fiedler, MD, Katharina Götze, MD, Mark Ringhoffer, MD, Jan Schleicher, MD, Elisabeth Lange, MD, Gerhard Held, MD, Martin Griesshammer, MD, Richard Greil, MD, Heinz Kirchen, MD, Elisabeth Koller, MD, Felicitas Thol, MD, Jürgen Krauter, MD, Michael Heuser, MD, Arnold Ganser, MD, Lars Bullinger, MD, Richard F. Schlenk, MD, Hartmut Döhner, MD, Konstanze Döhner, MD
Journal: Blood
Blood (2016) 128 (22): 1207.
https://doi.org/10.1182/blood.V128.22.1207.1207
Published: 2016
Journal Articles

Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All- Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients

Michael Lübbert, MD, Olga Grishina, Claudia Schmoor, Richard F. Schlenk, MD, Edgar Jost, Jürgen Krauter, MD, Michael Heuser, MD, Felicitas Thol, MD, Marcus M. Schittenhelm, Helmut R. Salih, Andrea Kündgen, MD, Ulrich Germing, Katharina Götze, Hans-Walter Lindemann, Carsten Müller-Tidow, Gerhard Heil, Gesine Bug, Carsten Schwänen, Aristoteles Giagounidis, Sebastian Scholl, Andreas Neubauer, Wolfram Brugger, Maike de Wit, Sebastian Schroll, Stephan Kremers, Elisabeth Lange, MD, Johannes Kullmer, Dirk Behringer, Matthias Egger, Irmgard Dresel, Tobias Dechow, Dietger Niederwieser, MD, Maxi Wass, Annette M. May, Ralph Wäsch, MD, Konstanze Döhner, Arnold Ganser, MD, Björn Hackanson, Hartmut Döhner, MD
Journal: Blood
Blood (2016) 128 (22): 589.
https://doi.org/10.1182/blood.V128.22.589.589
Published: 2016
Journal Articles

Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara F. Eichhorst, MD, Jasmin Bahlo, Christian Maurer, MD, Elisabeth Lange, MD, Hubert Köppler, Prof., Michael G Kiehl, MD, Martin Sökler, MD, Rudolf Schlag, Ursula Vehling-Kaiser, MD, Georg Köchling, MD, Christoph Plöger, MD, Michael Gregor, Torben Plesner, MD, Marco Herling, MD PhD, Kirsten Fischer, Hartmut Döhner, MD, Michael Kneba, Clemens Wendtner, MD, Wolfram Klapper, MD, Karl-Anton Kreuzer, Sebastian Böttcher, Stephan Stilgenbauer, Anna Maria Fink, MD, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 4382.
https://doi.org/10.1182/blood.V128.22.4382.4382
Published: 2016
Journal Articles

Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG)

Othman Al-Sawaf, MD, Sandra Robrecht, Jasmin Bahlo, Anna Maria Fink, MD, Paula Cramer, MD, Christian Maurer, MD, Manuela A. Bergmann, MD, Martin H. Dreyling, MD PhD, Elisabeth Lange, MD, Michael Kneba, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Michael G Kiehl, MD, Ulrich Jäger, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, Michael Hallek, Barbara F. Eichhorst, MD, Georg Hopfinger, MD
Journal: Blood
Blood (2016) 128 (22): 4394.
https://doi.org/10.1182/blood.V128.22.4394.4394
Published: 2016
Journal Articles

Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3 -ITD: Interim-Analyses of the AMLSG 16-10 Trial

Richard F. Schlenk, MD, Walter Fiedler, MD, Helmut R. Salih, MD, Gerald Wulf, MD, Felicitas Thol, MD, Andrea Kündgen, MD, Thomas Kindler, MD, Hans-Juergen Salwender, MD, Michael Lübbert, MD, Peter Brossart, MD, Jörg Westermann, MD Prof, Doris Kraemer, MD, Katharina Goetze, MD, Heinz-August Horst, MD PhD, Jürgen Krauter, MD, Michael Girschikofsky, MD, Mark Ringhoffer, MD, Thomas Südhoff, MD, Gerhard Held, MD, Hartmut H. Kirchner, MD, Wolff Schmiegel, MD, Richard Greil, MD, Martin Griesshammer, MD, Elisabeth Lange, MD, Uwe Martens, MD, Bernd Hertenstein, MD, Maike de Wit, Elisabeth Koller, MD, Andreas L. Petzer, MD, Tanja Hesse, MD, Volker Runde, MD, Peter Reimer, MD, Beate S. Schultheis, MD, Heinz Kirchen, MD, Frank Griesinger, MD, Holger Hebart, MD, Gerhard Heil, Stephan Kremers, David Nachbaur, MD, Nadezda Basara, MD, Carsten Schwänen, Daniel Schöndube, MD, Jochen Greiner, Anja Münnich, Daniela Weber, Verena I. Gaidzik, MD, Maria-Veronica Teleanu, MD, Peter Paschka, MD, Frauke Theis, Axel Benner, Michael Heuser, MD, Konstanze Döhner, MD, Arnold Ganser, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2016) 128 (22): 449.
https://doi.org/10.1182/blood.V128.22.449.449
Published: 2016
Journal Articles

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara Eichhorst, MD, Anna Maria Fink, MD, Raymonde Busch, Gabor Kovacs, MD, Christian Maurer, MD, Elisabeth Lange, MD, Hubert Köppler, Prof. Dr., Michael G Kiehl, MD, Martin Soekler, MD, Rudolf Schlag, Ursula Vehling-Kaiser, MD, Georg R.A. Köchling, MD, Christoph Plöger, MD, Michael Gregor, MD, Torben Plesner, MD, Marek Trneny, MD, Kirsten Fischer, Hartmut Döhner, MD, Michael Kneba, MD PhD, Clemens-Martin Wendtner, MD, Wolfram Klapper, MD, Karl Anton Kreuzer, Prof. Dr. MD, Stephan Stilgenbauer, MD PhD, Sebastian Böttcher, MD, Michael Hallek, MD
Journal: Blood
Blood (2014) 124 (21): 19.
https://doi.org/10.1182/blood.V124.21.19.19
Published: 2014
Journal Articles

Elderly CML Patients On Early Applied High Dose Imatinib Achieve Molecular Remissions As Fast As Younger Patients In Contrast To Patients On Standard Dose Imatinib: A Subanalysis Of The German CML-Study IV

Ulrike Proetel, MD, Nadine Pletsch, MD, Michael Lauseker, Lida Kalmanti, MD, Annette Schreiber, MD, Martin C. Müller, MD, Benjamin Hanfstein, MD, Stefan W. Krause, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Wolf-Karsten Hofmann, MD, Elisabeth Lange, MD, Hermann Einsele, MD, Martin Wernli, MD, Stephan Kremers, MD, Rudolf Schlag, MD, Lothar Müller, MD, Matthias Hänel, MD, Hartmut Link, MD, Bernd Hertenstein, MD, Markus Pfirrmann, PhD, Andreas Hochhaus, MD, Joerg Hasford, MD, Rüdiger Hehlmann, MD, Susanne Saussele, MD
Journal: Blood
Blood (2013) 122 (21): 96.
https://doi.org/10.1182/blood.V122.21.96.96
Published: 2013
Journal Articles

Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG)

Barbara Eichhorst, MD, Anna-Maria Fink, MD, Raymonde Busch, PhD, Elisabeth Lange, MD, Hubert Köppler, Michael Kiehl, MD, Martin Sökler, MD, Rudolf Schlag, MD, Ursula Vehling-Kaiser, MD, Georg Köchling, MD, Christoph Plöger, MD, Michael Gregor, MD, Torben Plesner, MD, Marek Trneny, MD, Ph.D., Kirsten Fischer, MD, Hartmut Döhner, MD, Michael Kneba, MD, Clemens Wendtner, MD, Wolfram Klapper, Karl-Anton Kreuzer, Stephan Stilgenbauer, MD, Sebastian Böttcher, MD, Michael Hallek, MD
Journal: Blood
Blood (2013) 122 (21): 526.
https://doi.org/10.1182/blood.V122.21.526.526
Published: 2013
Journal Articles

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)

Richard F Schlenk, MD, Wolfgang Herr, MD, Gerald Wulf, Helmut R Salih, MD, Jürgen Krauter, Prof. Dr. med., Hans Guenter Derigs, MD, Andrea Kündgen, Mark Ringhoffer, MD, Uwe M. Martens, MD, Bernd Hertenstein, Martin Griesshammer, MD, PhD, Michael Girschikofsky, MD, Helga Bernhard, MD, Jens Kersten, MD, Maria von Lilienfeld-Toal, MD, Elisabeth Koller, MD, Elisabeth Lange, MD, Jörg Westermann, MD, Daniela Späth, MSc, Gudrun Göhring, MD, Veronica Teleanu, MD, Axel Benner, Dipl.Stat., Konstanze Döhner, MD, Arnold Ganser, Hartmut Döhner, MD
Journal: Blood
Blood (2012) 120 (21): 412.
https://doi.org/10.1182/blood.V120.21.412.412
Published: 2012